Corcept Therapeutics
CORT
201 hedge funds and large institutions have $1.59B invested in Corcept Therapeutics in 2021 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 62 increasing their positions, 78 reducing their positions, and 21 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
19% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 21
1% more funds holding
Funds holding: 199 → 201 (+2)
0.72% more ownership
Funds ownership: 69.04% → 69.76% (+0.72%)
10% less capital invested
Capital invested by funds: $1.77B → $1.59B (-$177M)
21% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 78
38% less call options, than puts
Call options by funds: $4.2M | Put options by funds: $6.78M
Top Buyers
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$17.9M |
| 2 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
+$6.52M |
| 3 |
EIP
Epoch Investment Partners
New York
|
+$4.21M |
| 4 |
Goldman Sachs
New York
|
+$3.47M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$3.3M |
Top Sellers
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$25.4M |
| 2 |
Renaissance Technologies
New York
|
-$5.74M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$4.69M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$4.03M |
| 5 |
LSV Asset Management
Chicago,
Illinois
|
-$3.64M |
CORT Hedge Fund Activity: Q3 2021 in Review
201 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q3 2021, worth a combined $1.59B — down 10% from $1.77B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CORT positions and 21 closed out — a net gain of 4 holders — while 62 added to existing stakes and 78 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $17.9M. The largest seller was Federated Hermes, cutting an estimated $25.4M.
- 201 institutional investors held Corcept Therapeutics (CORT) as of Q3 2021, up from 199 in Q2 2021.
- Funds reported $1.59B of Corcept Therapeutics stock for Q3 2021, down 10% quarter-over-quarter.
- 25 funds opened new Corcept Therapeutics positions in Q3 2021 and 21 closed out, a net change of +4 holders.
- The largest Corcept Therapeutics buyer in Q3 2021 was Arrowstreet Capital, an estimated $17.9M added.
- The largest Corcept Therapeutics seller in Q3 2021 was Federated Hermes, an estimated $25.4M sold.
Based on aggregated 13F filings for Q3 2021.